SUMMIT, N.J. - Celgene Corp. said Thursday that a competitor withdrew its application for a generic version of Celgene's cancer drug Thalomid.
Celgene said Barr Laboratories withdrew the application, which had been filed in 2006 with the Food and Drug Administration.
As a result, Celgene said it had dropped a 2007 patent infringement lawsuit against Barr.
Celgene markets Thalomid, or thalidomide, as a treatment for multiple myeloma, which is a cancer that affects bone marrow.
The company filed suit against Barr Pharmaceuticals in January 2007, saying Barr's proposed generic violated patents held by Celgene.